Provectus announces up to $10M convertible loan financing at 8% interest

PROVECTUS BIOPHARMACEUTICALS, INC.

Board approved term sheet for up to $10M unsecured convertible loan (2024 Financing) from multiple investors.
Loan bears 8% annual interest, matures in 12 months, convertible into Series D-1 Preferred at $2.8620/share.
Series D-1 Preferred convertible into 10 shares of common stock per preferred share.
Proceeds will fund drug discovery and development programs and G&A expenses.
Also closed previously reported 2022 Financing totaling $4,865,500 as of July 11, 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.